SCHEMBL24036221

SCHEMBL24036221

Bc1ccc(S(=O)(=O)c2ccc(B)cn2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTR2A P28223 2/20 0.47
▸ KCNH2 Q12809 2/20 0.47
▸ AGTR1 P30556 1/20 0.47
▸ HSP90AA1 P07900 2/20 0.46
▸ CXCR5 P32302 2/20 0.46
▸ APLNR P35414 2/20 0.46
▸ CCR6 P51684 2/20 0.46
▸ RAB9A P51151 1/20 0.46
▸ GFER P55789 1/20 0.46
▸ KMT2A Q03164 1/20 0.46
▸ PKM P14618 2/20 0.41
▸ KDM4E B2RXH2 2/20 0.41
▸ HTT P42858 3/20 0.37
▸ LMNA P02545 1/20 0.37
▸ MAPT P10636 1/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ CYP11B1 P15538 1/20 0.36
▸ CYP11B2 P19099 1/20 0.36
▸ AKR1B1 P15121 6/20 0.35
▸ CA12 O43570 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23988486 0.83 AKR1B1 (0.39) HTR2AKCNH2AGTR1HSP90AA1CXCR5
SCHEMBL22990154 0.77 CA12 (0.32) HTR2AKCNH2AGTR1HSP90AA1CXCR5
SCHEMBL21556044 0.75 CA2 (0.61) CA12CA1CA2CA4CA6
SCHEMBL13266077 0.75 CA12 (0.36) CA12CA1CA2CA4CA6
SCHEMBL21627142 0.75 ALDH1A1 (0.52) KMT2APKMKDM4ELMNAMAPT
SCHEMBL29397251 0.72 CA12 (0.62) HTR2AKCNH2AGTR1HSP90AA1CXCR5
SCHEMBL10834173 0.72 AGTR1 (0.65) HTR2AKCNH2AGTR1HSP90AA1CXCR5
SCHEMBL25356808 0.67 HTR2A (0.62) HTR2AKCNH2AGTR1HSP90AA1CXCR5
SCHEMBL20379895 0.67 KMT2A (0.56) HTR2AKCNH2AGTR1HSP90AA1CXCR5
SCHEMBL3158170 0.67 HTR2A (0.62) HTR2AKCNH2AGTR1HSP90AA1CXCR5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210355378-A9 HETEROCYCLIC COMPOUNDS EXHIBITING THERMALLY ACTIVATED DELAYED FLUORESCENCE (TADF) AND THEIR USE IN ELECTROLUMINESCENT DEVICES UNIVERSITY COURT OF THE UNIVERSITY OF ST ANDREWS (GB) 2021-11-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210355378-A9 HETEROCYCLIC COMPOUNDS EXHIBITING THERMALLY ACTIVATED DELAYED FLUORESCENCE (TADF) AND THEIR USE IN ELECTROLUMINESCENT DEVICES ETFA, TEAD2, TERF2 HTR2A 618/4885KCNH2 569/4885AGTR1 3686/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback